These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 8561141

  • 1. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine.
    Sandborn WJ, Tremaine WJ, Lawson GM.
    Am J Gastroenterol; 1996 Jan; 91(1):37-43. PubMed ID: 8561141
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
    Egan LJ, Sandborn WJ, Tremaine WJ.
    Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
    [Abstract] [Full Text] [Related]

  • 3. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease.
    Sandborn WJ.
    Am J Gastroenterol; 1997 May; 92(5):876-9. PubMed ID: 9149205
    [Abstract] [Full Text] [Related]

  • 4. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
    Dejaco C, Gasché C, Reinisch W, Moser G, Novacek G, Tillinger W, Vogelsang H, Gangl A.
    Wien Klin Wochenschr; 1998 Sep 04; 110(16):579-84. PubMed ID: 9782579
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children.
    Mahdi G, Israel DM, Hassall E.
    Am J Gastroenterol; 1996 Jul 04; 91(7):1355-9. PubMed ID: 8677994
    [Abstract] [Full Text] [Related]

  • 6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 04; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 7. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
    Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF.
    Am J Gastroenterol; 1998 Oct 04; 93(10):1860-6. PubMed ID: 9772045
    [Abstract] [Full Text] [Related]

  • 8. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease.
    Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, Pajares Garcia JM, Mate-Jimenez J.
    Hepatogastroenterology; 1999 Oct 04; 46(28):2265-8. PubMed ID: 10521978
    [Abstract] [Full Text] [Related]

  • 9. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.
    Hinterleitner TA, Petritsch W, Aichbichler B, Fickert P, Ranner G, Krejs GJ.
    Z Gastroenterol; 1997 Aug 04; 35(8):603-8. PubMed ID: 9297775
    [Abstract] [Full Text] [Related]

  • 10. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X, Serre-Debeauvais F, Phelip JM, Faucheron JL, Hardy G, Chartier A, Helluwaert F, Bessard G, Bonaz B.
    Aliment Pharmacol Ther; 2005 Apr 01; 21(7):829-39. PubMed ID: 15801918
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine for induction of remission in Crohn's disease.
    McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK.
    Cochrane Database Syst Rev; 2005 Apr 18; (2):CD000297. PubMed ID: 15846602
    [Abstract] [Full Text] [Related]

  • 12. Oral butyrate for mildly to moderately active Crohn's disease.
    Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S, Corazza GR.
    Aliment Pharmacol Ther; 2005 Nov 01; 22(9):789-94. PubMed ID: 16225487
    [Abstract] [Full Text] [Related]

  • 13. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
    Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R.
    N Engl J Med; 1994 Jun 30; 330(26):1846-51. PubMed ID: 8196727
    [Abstract] [Full Text] [Related]

  • 14. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
    Frieri G, Pimpo MT, Palumbo G, Tonelli F, Annese V, Sturniolo GC, Andreoli A, Comberlato M, Corrao G, Caprilli R.
    Am J Gastroenterol; 2000 Jun 30; 95(6):1486-90. PubMed ID: 10894584
    [Abstract] [Full Text] [Related]

  • 15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May 01; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

  • 17. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial.
    D'Haens G, Swijsen C, Noman M, Lemmens L, Ceuppens J, Agbahiwe H, Geboes K, Rutgeerts P.
    Am J Gastroenterol; 2001 Sep 01; 96(9):2564-8. PubMed ID: 11569676
    [Abstract] [Full Text] [Related]

  • 18. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A, Griga T, May B.
    Hepatogastroenterology; 1999 Sep 01; 46(30):3124-35. PubMed ID: 10626173
    [Abstract] [Full Text] [Related]

  • 19. Intravenous cyclosporine for inflammatory bowel disease--safe and effective.
    Chermesh I, Tamir A, Lachter J, Eliakim R.
    Hepatogastroenterology; 2007 Sep 01; 54(79):2003-6. PubMed ID: 18251148
    [Abstract] [Full Text] [Related]

  • 20. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach.
    Margalit M, Israeli E, Shibolet O, Zigmond E, Klein A, Hemed N, Donegan JJ, Rabbani E, Goldin E, Ilan Y.
    Am J Gastroenterol; 2006 Mar 01; 101(3):561-8. PubMed ID: 16542292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.